Bausch Health's debt burden and potential bankruptcy risks are mitigated by the likely sale of Bausch + Lomb, which could ... firm would be the most viable solution, but at what price?

This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

The Financial Times reported Bausch + Lomb is in talks with advisors to potentially sell itself. It had formerly sought to spin off from parent Bausch Health in a stock-for-stock deal. But Bausch ...

Eye-care company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Bausch + Lomb Corp. shares rose the most ever following a report that the eye care company is considering selling itself to disentangle from its debt-laden parent company. The Financial Times ...

Shares of Bausch + Lomb (NYSE: BLCO) rallied 15.7% as of 3:07 p.m. ET today. The stock is surging today on news the company is considering selling itself. Of note, Bausch + Lomb is the eye-care ...

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...